A New Approach to Conjugate Vaccines

Company Overview

TRIA Bioscience is a privately-held company focusing on the development of a new generation of conjugate vaccines. Scientists at TRIA are using a proprietary synthetic peptide to achieve robust immune responses to traditionally weak antigens. These vaccines are very simple in design, their targets are specific, and their reduced manufacturing costs are unmatched by current technologies.

Our Team

Chris Clegg PhD, President, Founder, and CSO:

Chris has more than 30 years experience in biomedical research with an emphasis on the discovery and development of immune-based therapeutics. Prior experience includes Vice President of Scientific Affairs at Immune Design, Research Director at Zymogenetics, and Principle Scientist with Bristol-Myers Squibb. He received his scientific training in biochemistry and molecular biology at the University of Washington.

Chris Clegg, PhD
President, Founder, and CSO

David Zeigler PhD, Senior Scientist:

Dave is expert in peptide chemistry and is the scientific lead for our vaccine portfolio. His responsibilities include experimental design and implementation, project management and supervising external alliances. He received his PhD in Chemistry from the University of Washington, focusing on the synthesis of conductive polymers for energy generation and storage.

David Zeigler, PhD
Senior Scientist

Richard Roque, Scientist:
Richard is an expert in vaccinology and measuring immune responses both in vivo and in vitro. His responsibilities include protocol development and execution, data interpretation/analysis, and managing external studies at CROs and collaborators. Richard has worked in biomedical research for more than 25 years with prior employment at ZymoGenetics, the Fred Hutchinson Cancer Research Center, the University of Chicago, and the University of Washington.

Richard Roque
Scientist

Marcia Tapp, Finance and Administration Officer:

Marcia is an experienced Finance and Administrative Officer with a demonstrated history of working in the biotechnology industry. Her responsibilities include grants and finance management, administration, facilities, and human resources. Prior employment includes KitoTech Medical, Hemaquest Pharmaceuticals, Infectious Disease Research Institute, Immune Design, and Dharma Therapeutics.

Marcia Tapp
Finance and Administration Officer

Technology

Background

Conjugate vaccines are among the most successful vaccines developed to date with combined sales of nearly $10B per year. Current conjugate vaccines are very effective in preventing pneumonia and meningitis and induce antibodies to bacterial polysaccharides. This technology requires the chemical conjugation of weak antigens to a protein carrier to improve immunogenicity.

The Problem

Despite their success, conjugate vaccines are expensive to manufacture, and the protein carriers and conjugation reactions create problems that diminish vaccine activity. Unfortunately, new conjugate vaccines for infectious disease have not been approved, nor has this approach succeeded in treating diseases that use other weak antigens including carbohydrates, short peptides, and small molecule drugs.

Our Solution

TRIA Bioscience is pioneering a new approach to conjugate vaccines where traditional protein carriers are replaced with a much smaller synthetic peptide and antigens are attached using new proprietary methods. These vaccines are very simple in design and their manufacturing generates a cost-effective product unmatched by current technologies.

A New Conjugate Vaccine Carrier

  • Synthetic peptide just 65 amino acids in length
  • Two functional domains that activate B- (blue) and T-cells (green)
  • Eliminates the complexities of traditional vaccine carriers
  • Streamlines manufacturing and the regulatory approval process

Pipeline

THERAPEUTIC AREA TARGET DISCOVERY ANIMAL PROOF
OF CONCEPT
MFG TOX PHASE 1
Addiction Nicotine
 
Animal Healh Immunocastration
 
Viral Infection Influenza
 
Alzheimer's Disease Beta-Amyloid
 
Tau
 
Brain Injury Tau
 

Addiction

TRIA Bioscience has built a vaccine platform for treating drug addiction that includes nicotine. Smoking is the second leading cause of death in the world.  An estimated 1.3 billion people use tobacco products and 50% of these users will die from a smoking related disease.  This project is being funded by a $6.3M grant from the National Institute of Drug Abuse.

Animal Health

The second candidate is an animal health product that provides a safe more humane and economical alternative to surgical castration of food source livestock. Additional uses includes fertility and overpopulation control of domestic animals and wildlife.

Contact

TRIA Bioscience Corp.
1616 Eastlake Ave E, Suite 260
Seattle, WA 98102

*
*
*
*